Survival and treatment response in adults with acute promyelocytic leukemia treated with a modified International Consortium on Acute Promyelocytic Leukemia protocol
Rev. bras. hematol. hemoter
;
38(4): 285-290, Oct.-Dec. 2016. tab, graf
Article
Dans Anglais
| LILACS
| ID: biblio-829950
ABSTRACT
ABSTRACT Acute promyelocytic leukemia has good prognosis in view of the high complete remission and survival rates achieved with therapies containing all-trans retinoic acid or arsenic trioxide. However, there is a significant risk of death during induction due to hemorrhage secondary to disseminated intravascular coagulation. This has contributed to a gap in the prognosis of patients between developed and developing countries. The International Consortium on Acute Promyelocytic Leukemia was created in 2005 and proposed a treatment protocol based on daunorubicin and all-trans retinoic acid stratified by risk geared toward developing countries. Herein are presented the results from the first patient cohort treated in a single developing country hospital employing a slightly modified version of the International Consortium protocol in a real life setting. Twenty patients with acute promyelocytic leukemia were enrolled 27.8% had low-risk, 55.6% intermediate risk and 16.7% high-risk. The complete remission rate was 94.4% after a median of 42 days. Both relapse rates and death rates were one patient (5.5%) each. No deaths were observed during consolidation. After a median follow-up of 29 months, the overall survival rate was 89.1%. Efficacy and safety of the International Consortium on Acute Promyelocytic Leukemia protocol has been reproduced in acute promyelocytic leukemia patients from a developing country.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Leucémie aiguë promyélocytaire
/
Protocoles cliniques
/
Récepteur-1 au facteur croissance endothéliale vasculaire
/
Consortiums de Santé
Type d'étude:
Guide de pratique
/
Étude pronostique
langue:
Anglais
Texte intégral:
Rev. bras. hematol. hemoter
Thème du journal:
Hématologie
Année:
2016
Type:
Article
Pays d'affiliation:
Mexique
Institution/Pays d'affiliation:
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán/MX
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS